Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
Aerie Pharma (AERI) Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
AERIE PHARMACEUTICALS, INC. - Aerie Pharmaceuticals, Inc. Trademark Registration
Aerie Looks to Japanese Market for Eye Drug, Opens Tokyo Office | North Carolina Biotechnology Center
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Compliance Program | Aerie Pharmaceuticals, Inc.
Aerie Pharma on go with mid-stage study of eye drop for dry eye (NASDAQ:AERI) | Seeking Alpha
Aerie Pharmaceuticals | WRAL TechWire
Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration | Business Wire
AeriePharma (@AeriePharma) | Twitter
Aerie Pharma slips after announcing eye disease trial failed to meet primary endpoints | Seeking Alpha
Casey Kopczynski - Chief Scientific Officer and Founder - Aerie Pharmaceuticals, Inc | LinkedIn
Aerie Pharmaceuticals Employees, Location, Careers | LinkedIn
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Our Eye Care Products | Aerie Pharmaceuticals, Inc.
Investor Relations | Aerie Pharmaceuticals, Inc
Aerie Pharma Re-Ups In Irvine, CEO Departs | Orange County Business Journal
Aerie Pharmaceuticals Inc - ZIP 27703, NAICS 423450
Aerie Pharmaceuticals (Nasdaq: AERI) acquires Spanish company Avizorex Pharma - Triangle Business Journal
Working at Aerie Pharmaceuticals | Glassdoor
